All In Biotech

Drug Trial Radar · NCT06544330

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Apr 2028

Study completion Apr 2041

Sponsor

Lead sponsor
SynthekineIndustry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.

Conditions

  • Systemic Lupus Erythematosus
  • Lupus Nephritis
  • Systemic Sclerosis

Interventions

  • SYNCAR-001Drug

    SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb

  • STK-009Drug

    STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicities (DLTs)Time frame: Up to 28 days after SYNCAR-001 infusion
  2. Adverse EventsTime frame: Up to 96 weeks after SYNCAR-001 infusion

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Feinstein Institutes for Medical Research

    Manhasset, New York

  • Columbia University Irving Medical Center

    New York, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.